logo

For the Inventor, By the Inventor

Nagaokakyo, Japan

Hideo Shirafuji

This inventor holds 9 USPTO granted patents. Top assignee: Takeda Chemical Industries, Inc.. Active years: 1984-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideo Shirafuji. Retrieved from https://idiyas.com/inventor/hideo-shirafuji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 40(Granted Patents)


Location History:

  • Nagaokakyo, JP (1984 - 1996)
  • Kyoto, JP (1997 - 1999)

Company Filing History:

goldMedal9 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1984-1999

Loading Chart...
9 patents (USPTO):Explore Patents
1. 5883075 - Cyclic endothelin antagonists (1999-03-16),
2. 5616684 - Cyclic peptides and use thereof (1997-04-01),
3. 5523305 - Tachykinin receptor antagonists, isoquinolones and their production (1996-06-04),
4. 5474924 - Method for producing 2-keto-L-gulonic acid (1995-12-12),
5. 5310741 - TAN-1251 compounds and their production from penicillium thomii (1994-05-10),
6. 4904588 - Method for producing L-sorbose (1990-02-27),
7. 4877735 - Process for producing 2-keto-L-gulonic acid (1989-10-31),
8. 4876195 - Process for producing 2-keto-D-glucaric acid (1989-10-24),
9. 4465771 - Production of enduracidin and microorganisms therefor (1984-08-14),

Title: Hideo Shirafuji: Innovator in Cyclic Peptide Research

Introduction

Hideo Shirafuji is a prominent inventor based in Nagaokakyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of cyclic peptides. With a total of 9 patents to his name, Shirafuji's work has advanced the understanding and application of peptide-based therapeutics.

Latest Patents

Shirafuji's latest patents include groundbreaking research on cyclic endothelin antagonists. One of his notable inventions is a cyclic hexapeptide represented by a specific formula, which includes various amino acid residues. This invention also encompasses a pharmaceutical composition that utilizes this peptide as an active ingredient. Additionally, he has developed cyclic peptides that exhibit antagonistic activity on endothelin receptors and NK2 receptors. These peptides are characterized by their unique formula, which allows for various substitutions, enhancing their therapeutic potential.

Career Highlights

Hideo Shirafuji is currently associated with Takeda Chemical Industries, Inc., a leading pharmaceutical company. His work at Takeda has been instrumental in advancing peptide research and developing innovative therapeutic solutions. His contributions have not only enriched the scientific community but have also paved the way for new treatment options in medicine.

Collaborations

Shirafuji has collaborated with esteemed colleagues such as Ikuo Nogami and Takamasa Yamaguchi. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of pharmaceutical research.

Conclusion

Hideo Shirafuji's contributions to cyclic peptide research and his innovative patents have significantly impacted the pharmaceutical industry. His work continues to inspire future advancements in peptide-based therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…